Dr. George Kontopidis received his PhD in Structural Biology from the University Edinburgh UK. He continued his Research in protein ligand interaction after his PhD in Edinburgh University in protein ligand interactions. Dr George Kontopidis jointed Cyclacel Pharmaceutical Ltd in Dundee UK, a Biotech company founded by Prof. Sir David Lane, in 2000 where he contributed to the early discovery process of anti-cancer drugs for target proteins Cyclin A, CDKs and PCNA. From 2006 is holding a position in University of Thessaly in Greece now as full professor.
His expertise covers the area of structure based drug design from protein purification to computational modelling. The laboratory techniques and methods used in order to achieve the above goal includes protein production and purification (chromatographic method), protein characterisation using biophysical (fluorescence, calorimetry), structure determination (X-ray crystallography) and protein modelling.
Fulbright Foundation will provide the opportunity to join forces with colleagues from South Carolina University in an effort to design better inhibitors for B-Raf protein that could result in potential anticancer drugs. The main objective of the collaborative research project is “Structural and Functional studies in oncoprotein B-Raf”.